Qiagen Sees Unusually Large Options Volume (NYSE:QGEN)

Qiagen N.V. (NYSE:QGEN) was the recipient of unusually large options trading on Monday. Stock investors acquired 6,107 call options on the company. This represents an increase of 176% compared to the typical volume of 2,214 call options.

Institutional Trading of Qiagen

Several large investors have recently made changes to their positions in the company. United Services Automobile Association acquired a new position in Qiagen during the 1st quarter valued at about $239,000. Prudential Financial Inc. boosted its stake in Qiagen by 74.9% during the 2nd quarter. Prudential Financial Inc. now owns 8,873 shares of the company’s stock valued at $426,000 after purchasing an additional 3,799 shares during the last quarter. Invesco Ltd. boosted its stake in Qiagen by 123.7% during the 2nd quarter. Invesco Ltd. now owns 1,006,025 shares of the company’s stock valued at $48,350,000 after purchasing an additional 556,387 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in Qiagen by 226.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock valued at $125,000 after purchasing an additional 1,802 shares during the last quarter. Finally, First Trust Advisors LP acquired a new position in Qiagen during the 2nd quarter valued at about $3,639,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Stock Performance

Shares of QGEN opened at $38.15 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 3.90 and a quick ratio of 3.31. The stock has a 50-day moving average of $42.66 and a 200-day moving average of $47.06. The company has a market cap of $7.86 billion, a PE ratio of 18.92, a P/E/G ratio of 1.99 and a beta of 0.79. Qiagen has a one year low of $37.40 and a one year high of $57.81.

Qiagen (NYSE:QGEN) last issued its earnings results on Wednesday, February 4th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.61 by $0.01. The company had revenue of $540.42 million during the quarter, compared to the consensus estimate of $528.53 million. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period last year, the business posted $0.61 EPS. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. On average, equities research analysts predict that Qiagen will post 2.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on QGEN shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Qiagen in a report on Friday, March 27th. Citigroup decreased their price target on Qiagen from $55.40 to $55.00 and set a “neutral” rating for the company in a report on Friday, February 6th. Robert W. Baird set a $53.00 price target on Qiagen in a report on Friday, February 6th. UBS Group set a $52.00 target price on Qiagen in a research note on Monday, February 9th. Finally, JPMorgan Chase & Co. raised their target price on Qiagen from $55.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. Four equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Qiagen has an average rating of “Hold” and an average target price of $53.64.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.